Drugs / IBI353
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05490316 | Nov 2022 | — | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-12-05 | Innovent Biologics (Suzhou) Co. Ltd. | Innovent and UNION Therapeutics Announce First Subject Dosed in a Chinese Clinical Phase I Study of the Novel PDE4 Inhibitor Orismilast (IBI353) innoventbio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI353 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05490316 ↗ |
| Known as | Orismilast | “IBI353 (Orismilast)” NCT05490316 ↗ |
| Route | Oral | “modified-release IBI353 administered orally” NCT05490316 ↗ |